22 Favipiravir pharmacokinetics in immunocompromised infants and children with chronic RNA viral infections
Sign Up to like & getrecommendations! Published in 2023 at "Archives of Disease in Childhood"
DOI: 10.1136/archdischild-2023-esdppp.22
Abstract: Introduction Favipiravir selectively inhibits RNA polymerase responsible for single-stranded viral replication. It is licensed for treating influenza and repurposed to treat other diseases such as Ebola and COVID-19. It is metabolised by hepatic aldehyde oxidase… read more here.
Keywords: immunocompromised infants; pharmacokinetics immunocompromised; favipiravir pharmacokinetics; model ... See more keywords